SCHEMBL2274104

SCHEMBL2274104

O=C(/C=C/c1ccc(O)cc1)Nc1cc(-c2ccccc2)ccc1C(=O)O

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPM2 O94759 5/20 0.76
LTB4R Q15722 4/20 0.76
TRPA1 O75762 5/20 0.60
TRPM8 Q7Z2W7 2/20 0.60
MMP1 P03956 5/20 0.58
MMP2 P08253 5/20 0.58
MMP9 P14780 5/20 0.58
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
MAPT P10636 1/20 0.56
RAB9A P51151 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HDAC2 Q92769 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
TOP2A P11388 1/20 0.55
TOP2B Q02880 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274109 1.00 TRPM2 (0.76) TRPM2LTB4RTRPA1TRPM8MMP1
SCHEMBL2271170 0.96 TRPM2 (0.70) TRPM2LTB4RTRPA1TRPM8MMP1
SCHEMBL2271172 0.96 TRPM2 (0.70) TRPM2LTB4RTRPA1TRPM8MMP1
SCHEMBL2269338 0.92 TRPM2 (0.75) TRPM2LTB4RTRPA1TRPM8MMP1
SCHEMBL2269335 0.92 TRPM2 (0.75) TRPM2LTB4RTRPA1TRPM8MMP1
SCHEMBL2271620 0.89 TRPA1 (0.73) TRPM2LTB4RTRPA1TRPM8MMP1
SCHEMBL2271618 0.89 TRPA1 (0.73) TRPM2LTB4RTRPA1TRPM8MMP1
SCHEMBL28809051 0.87 TRPM2 (1.00) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL28809046 0.87 TRPM2 (1.00) TRPM2LTB4RTRPA1TRPM8MEN1
SCHEMBL9973825 0.87 TRPM2 (0.62) TRPM2LTB4RTRPA1TRPM8MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 TRPM2 3539/4885LTB4R 2902/4885TRPA1 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.